| abstract |
The invention concerns the use of a compound depleting or temporarily inhibiting B cells, in the preparation of a composition to be administered to a patient in order to increase the T cell response specific to a vaccine, in particular a therapeutic vaccine, against a tumor or a chronic infection by a virus, parasite or another micro-organism. In a particular application, the composition is designed to be administered to a patient in order to increase the T cell response specific to a vaccine, in particular a therapeutic vaccine, comprising at least one inactivated human immunodeficiency virus (HIV). In particular, the depleting compound is an antibody, advantageously monoclonal, directed against the CD20 transmembrane antigen of pre-B cells or mature B cells. |